Billybob Jr. writes: Researchers at Dartmouth College and Medical School are finding continued success with synthetic triterpenoids, a new family of drugs they have developed. These compounds are potent inducers of the Nrf2 molecule that regulates the body's own antioxidant defenses. Conceived in the 1990s by two chemistry professors, the drugs "magnify the anti-inflammatory and anticancer properties of triterpenoids that occur naturally in plants" by nearly 500,000 times. In addition to Cancer, further research has also found significant results in the treatment and prevention of Diabetes, Alzheimer's, Parkinson's, chronic kidney disease, age-related macular degeneration and emphysema, and even obesity. The drugs are now being tested by Reata Pharmaceuticals in Phase I human trials.